Edition:
United Kingdom

People: Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

10.46EUR
16 Aug 2019
Change (% chg)

€0.22 (+2.15%)
Prev Close
€10.24
Open
€10.12
Day's High
€10.64
Day's Low
€10.10
Volume
29,249
Avg. Vol
42,381
52-wk High
€27.18
52-wk Low
€9.52

Mountfield, Richard 

Dr. Richard Mountfield has served as Vice President of Global Regulatory Affairs of CELYAD S.A. since February 3, 2016. Richard is a pharmaceutical professional with extensive Regulatory Affairs (preclinical, clinical, registration, and post-marketing) & Drug Development experience including leadership, management and project roles. Prior to joining Celyad he held positions in Europe and the US for a number of top 20 Pharmaceutical companies (Novo Nordisk, Roche, Boehringer Ingelheim and Novartis). He has been responsible for global regulatory strategy and submissions across a number of therapeutic areas. Most recently he was the global regulatory lead responsible for developing and implementing approvable strategies for a large multi-indication oncology program within Novartis. Richard holds a PhD in Biochemistry from Aberystwyth University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --